Financial Performance - Total revenue for 2024 was RMB 1,500,402 thousand, a decrease of 14.9% compared to RMB 1,763,734 thousand in 2023[9]. - Gross profit for 2024 was RMB 301,217 thousand, down 10.4% from RMB 336,050 thousand in 2023, with a gross margin of 20.1%[9]. - The company reported a profit attributable to owners of RMB 16,079 thousand for 2024, a significant recovery from a loss of RMB 113,473 thousand in 2023[9]. - In 2024, the company experienced a 14.9% decline in sales revenue, but managed to achieve a positive financial performance after significant losses in 2023[20]. - The net profit after tax for 2024 showed a turnaround from loss to profit, with order intake increasing by 12.1% compared to the same period in 2023[33]. - The total revenue for the year was approximately RMB 1,500.4 million, a decrease of about 14.9% compared to the previous year, primarily due to declines in the integrated process and packaging equipment systems and consulting, digitalization, and construction segments[81]. - The group recorded a profit before tax of approximately RMB 21.2 million, compared to a loss of RMB 34.4 million for the year ended December 31, 2023[106]. - The group reported a net profit of approximately RMB 13.6 million for the year, a significant improvement from a loss of RMB 151.3 million in the previous year[108]. Business Segments and Revenue Breakdown - Revenue contribution by business segment showed Integrated Process and Packaging Equipment & Systems at RMB 655,205 thousand (43.6%), Consulting, Digitalization and Construction at RMB 515,814 thousand (34.4%), and Life Science Equipment and Consumables at RMB 329,383 thousand (22.0%) for 2024[13]. - Revenue breakdown by business segment shows integrated process and packaging equipment systems at RMB 655.2 million (43.6%), consulting, digitalization, and construction at RMB 515.8 million (34.4%), and life science equipment and consumables at RMB 329.4 million (22.0%) for the year[82]. - The revenue from integrated process and packaging equipment systems decreased by RMB 207.9 million or 24.1% to RMB 655.2 million, mainly due to a reduction in uncompleted contracts[83]. - The revenue from consulting, digitalization, and construction decreased by RMB 81.5 million or 13.6% to RMB 515.8 million, attributed to a decline in uncompleted contract balances and delays in project starts[84]. - The revenue from life science equipment and consumables increased by RMB 26.0 million or 8.6% to RMB 329.4 million, driven by an increase in order volume and uncompleted contracts[85]. Assets and Liabilities - Total assets decreased by 3.5% to RMB 2,083,635 thousand as of December 31, 2024, compared to RMB 2,158,972 thousand in 2023[9]. - Net assets increased by 2.3% to RMB 793,468 thousand in 2024 from RMB 775,473 thousand in 2023[9]. - The asset-to-liability ratio improved to 33.9% in 2024 from 39.2% in 2023[9]. - The capital to debt ratio improved to approximately 33.9% as of December 31, 2024, compared to 39.2% as of December 31, 2023[113]. Market and Competitive Landscape - The biopharmaceutical sector is facing intense competition due to reduced capital expenditure, impacting profit margins significantly[21]. - The company is optimistic about order growth opportunities in 2025, contingent on market competition levels[21]. - Global expansion, particularly in sales, is a key action for 2025, with significant order breakthroughs in the US, South Korea, and India[22]. - The company faces intense competition in the pharmaceutical equipment and process systems market, which may lead to pricing pressure and impact financial performance[139]. Strategic Initiatives and Future Plans - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[16]. - The company consolidated six business divisions into three, aiming to adapt to market trends and improve resource allocation[20]. - The company aims to increase the share of its service business, which is less replicable and offers higher profit margins, by integrating environmental monitoring and testing systems into its service offerings in 2024[33]. - The company plans to restructure its business segments from six to three, aiming to enhance operational efficiency and adapt to competitive pressures starting in 2024[38]. - The company is focusing on continuous investment in technology and talent recruitment to strengthen its competitive advantage in the long term[38]. Research and Development - The company continues to invest in research and development to provide comprehensive solutions for existing and new customers[147]. - The group has developed 12 technology applications, including "Pharmaceutical Automation and Digitalization" and "Biopharmaceutical Processes and Technologies" to enhance its technical capabilities[74]. - The company is focusing on the development of microneedle drug delivery systems, which are gaining traction in the market due to their safety and efficacy[32]. - The application of artificial intelligence (AI) and machine learning (ML) in drug discovery is accelerating, creating opportunities for technological collaboration and digital investment[32]. Operational Efficiency and Cost Management - Selling and marketing expenses decreased by RMB 35.4 million or 21.2% to approximately RMB 131.9 million, mainly due to reductions in personnel costs and travel expenses[96]. - Administrative expenses decreased by approximately RMB 26.5 million or 19.8% to RMB 107.2 million for the year ended December 31, 2023, primarily due to reductions in personnel costs, professional fees, and auditor remuneration[99]. - The company emphasizes cost management to ensure project profit margins, with risks associated with project duration and labor costs[141]. Corporate Governance and Compliance - The company has adopted a corporate governance code to enhance management standards and protect shareholder interests[186]. - The company has confirmed compliance with the corporate governance code throughout the year, except for a deviation noted in the section regarding the chairman and CEO[193]. - The company’s board of directors has confirmed the independence of all independent non-executive directors, in accordance with listing rules[168]. Employee and Organizational Structure - As of December 31, 2024, the group had 1,445 full-time employees, a decrease of 165 employees compared to December 31, 2023[116]. - Employee costs for the year were approximately RMB 402.6 million, a reduction of about 12.4% from RMB 459.8 million for the year ended December 31, 2023[116]. - Employee performance evaluations are conducted annually, with a focus on maintaining good relationships and competitive compensation[145]. Environmental and Social Responsibility - The company is committed to sustainable development and compliance with environmental regulations, minimizing its carbon footprint[149]. - The company participates in the national pension scheme operated by the Chinese government, ensuring compliance for eligible employees in China and mandatory provident fund contributions for employees in Hong Kong[180].

Revenue and Profitability - Revenue for the year ended December 31, 2024, was RMB 1,500,402 thousand, a decrease of 14.9% from RMB 1,763,734 thousand in 2023[3] - Profit from continuing operations for the year was RMB 13,572 thousand, compared to a loss of RMB 34,789 thousand in 2023[4] - The company recorded a net profit of RMB 16,545 thousand for the year, a significant recovery from a loss of RMB 164,504 thousand in 2023[6] - The company reported a basic and diluted earnings per share of RMB 0.03 for continuing operations, compared to a loss of RMB 0.06 in 2023[5] - The company reported a profit attributable to owners of RMB 16,079,000 for the year ended December 31, 2024, compared to a loss of RMB 113,473,000 for the previous year[38] Expenses and Costs - Research and development expenses were RMB 53,549 thousand, slightly down from RMB 55,332 thousand in the previous year[4] - Employee costs, including directors' remuneration, decreased from RMB 459,799 thousand in 2023 to RMB 402,632 thousand in 2024, a reduction of about 12.4%[29] - Sales and marketing expenses decreased by 21.2% to approximately RMB 131.9 million, mainly due to reductions in personnel costs and travel expenses[127] - Administrative expenses decreased by approximately RMB 26.5 million or 19.8% to RMB 107.2 million for the year ended December 31, 2023, primarily due to reductions in personnel costs, professional fees, and auditor remuneration[128] Assets and Liabilities - Total assets decreased to RMB 2,083,635 thousand from RMB 2,158,972 thousand in 2023, while total equity increased to RMB 793,468 thousand from RMB 775,473 thousand[7] - Total liabilities decreased from RMB 1,383,499 thousand in 2023 to RMB 1,290,167 thousand in 2024, representing a reduction of approximately 6.7%[8] - Non-current liabilities decreased significantly from RMB 205,812 thousand in 2023 to RMB 101,481 thousand in 2024, a decline of about 50.7%[8] - Current liabilities increased slightly from RMB 1,177,687 thousand in 2023 to RMB 1,188,686 thousand in 2024, an increase of approximately 0.9%[8] Revenue Segmentation - Revenue from integrated engineering solutions amounted to RMB 1,038,332 thousand, contributing significantly to total revenue[16] - Sales revenue from goods reached RMB 382,264 thousand, showing a strong performance in product sales[16] - Service revenue totaled RMB 79,806 thousand, indicating growth in service offerings[16] - Revenue from mainland China declined from RMB 1,681,099 thousand in 2023 to RMB 1,333,487 thousand in 2024, representing a decrease of about 20.7%[26] Strategic Initiatives and Market Focus - The company has no plans for new product launches or market expansions mentioned in the report[4] - The company expects to continue focusing on market expansion and new product development as part of its strategic initiatives moving forward[20] - The company is restructuring its business into three major groups to enhance competitiveness in a challenging market environment[68] - The company plans to invest in top talent and consultants, which may negatively impact short-term profit margins but is expected to strengthen competitive advantages in the long run[68] Operational Efficiency and Improvements - Other income increased to RMB 27,548 thousand from RMB 11,706 thousand in the previous year, indicating improved operational efficiency[4] - The total expenses for continuing operations decreased from RMB 1,784,005 thousand in 2023 to RMB 1,491,810 thousand in 2024, a reduction of about 16.4%[28] - The company has implemented over 600 improvement suggestions and completed more than 90 improvement activities in 2024[79] Research and Development - The company incurred research and development expenses of RMB 55,332 thousand for the fiscal year ending December 31, 2023, indicating a commitment to innovation[22] - The group has developed 12 technology applications, including "Pharmaceutical Automation and Digitalization" and "Biopharmaceutical Processes and Technologies" to enhance its technical capabilities[104] Future Outlook - The company anticipates significant growth in GLP-1 drugs, antibody-drug conjugates, and autoimmune disease drugs by 2025[61] - The company is optimistic about the CGT industry, with ongoing investments in research and development for new products and services in this field[110] - The company plans to implement strategies focused on value-driven competition and global market expansion to enhance profitability and sustainable growth[126] Corporate Governance and Compliance - The audit committee, consisting of two independent non-executive directors and one non-executive director, reviewed the group's financial statements for the year[155] - The group's auditor confirmed that the figures in the preliminary results announcement are consistent with the audited financial statements[157] Shareholder Communication - The company expresses gratitude to shareholders and stakeholders for their support and acknowledges the efforts of all employees[159] - No dividends are recommended for the current year, consistent with the previous year[150]

AWSTAR 星生命科技有限公司 Interim Report 2024 中期報告 (Incorporated in the Cayman Islands with limited liability) Stock Code : 6118 2 0 2 4 2 0 2 4 中期報告 INTERIM REPORT 奥Austar Lifesciences Limited Austar Lifesciences Limited 奥星生命科技有限公司 Austar Lifesciences Limited 奥星生命科技有限公司 （於開曼群島註冊成立之有限公司） 股份代號：6118 目錄 | --- | --- | |------------------------------------|-------| | | | | 公司資料 | 2 | | 財務摘要 | 4 | | 管理層討論及分析 | 5 | | 企業管治及其他資料 | 31 | | 未經審核簡明合併財務報表的審閱報告 | 36 | | 中期簡明合併損益表 | 38 | | 中期簡明合併損益及其他綜合收益表 | 40 | | 中期簡明合併財務狀況表 | 41 ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 700,919 thousand, a decrease of 23.8% from RMB 919,457 thousand in the same period of 2023[2] - Gross profit for the same period was RMB 145,417 thousand, down 22.2% from RMB 186,933 thousand year-on-year[3] - Operating profit for the six months was RMB 17,254 thousand, compared to an operating loss of RMB 5,509 thousand in the previous year[3] - Profit attributable to owners of the company from continuing operations was RMB 5,877 thousand, recovering from a loss of RMB 7,379 thousand in the same period last year[4] - The company reported a net profit of RMB 4,189 thousand for the period, a significant recovery from a loss of RMB 72,186 thousand in the same period last year[5] - Total revenue for the group was approximately RMB 700.9 million for the six months ended June 30, representing a decrease of about 23.8% compared to the same period in 2023[72] Assets and Liabilities - Total assets as of June 30, 2024, were RMB 2,136,820 thousand, a slight decrease from RMB 2,158,972 thousand at the end of 2023[6] - As of June 30, 2024, total liabilities amounted to RMB 1,356,190 thousand, a decrease from RMB 1,383,499 thousand as of December 31, 2023, reflecting a reduction of approximately 2%[7] - Non-current liabilities decreased from RMB 205,812 thousand to RMB 168,564 thousand, representing a decline of about 18%[7] - Current liabilities totaled RMB 1,187,626 thousand, slightly up from RMB 1,177,687 thousand, indicating an increase of approximately 1%[7] - The total equity of the group increased to approximately RMB 780.6 million as of June 30, 2024, from approximately RMB 775.5 million as of December 31, 2023[101] Cash Flow - The net cash generated from operating activities for the period was approximately RMB 19.5 million, a significant improvement from a net cash used of RMB 64.8 million in the previous year[94] - The net cash generated from investing activities was approximately RMB 12.4 million, compared to a net cash used of RMB 25.4 million in the previous year[94] - The net cash used in financing activities amounted to approximately RMB 56.0 million, primarily due to loan repayments of RMB 185.8 million[94] Segment Performance - The integrated process and packaging systems segment generated revenue of RMB 309,273 thousand, while the life science equipment and consumables segment contributed RMB 175,060 thousand[12] - Revenue from the Integrated Process and Packaging Systems segment decreased by approximately RMB 147.3 million or 32.3% to about RMB 309.3 million[74] - Revenue from the Consulting, Digitalization, and Construction segment decreased by approximately RMB 85.1 million or 28.2% to about RMB 216.6 million[75] - Revenue from the Life Science Equipment and Consumables segment increased by approximately RMB 13.9 million or 8.6% to about RMB 175.1 million, primarily due to an increase in order volume during the review period[76] Orders and Contracts - Total orders from continuing operations reached approximately RMB 906.1 million, an increase of about RMB 186.4 million or 25.9% compared to RMB 719.7 million for the same period in 2023[43] - The Integrated Process and Packaging Systems segment reported orders of approximately RMB 430.7 million, up RMB 73.6 million or 20.6% from RMB 357.0 million in the previous year[44] - The Consulting, Digitalization, and Construction segment saw significant growth, with orders amounting to approximately RMB 290.5 million, an increase of RMB 95.9 million or 49.3% compared to RMB 194.6 million in the prior period[45] - The total value of uncompleted contracts as of June 30, 2024, was RMB 1,127.3 million, with 1,633 contracts in total[48] Research and Development - Research and development expenses for the six months ended June 30, 2024, were RMB 23,468 thousand, compared to RMB 27,465 thousand in the same period of 2023[14] - The company has developed core process equipment for biopharmaceuticals, enhancing product quality and increasing yield through streamlined production processes[54] - The company has created 24 new brochures and shared a total of 219 brochures on its resource center, enhancing global customer access to product and service information[53] Corporate Governance - The company acknowledges the importance of good corporate governance to enhance management standards and protect shareholder interests[108] - The board believes that having the same individual serve as both Chairman and CEO is beneficial for effective leadership and strategic planning[109] - The audit committee, established in October 2014, includes two independent non-executive directors and one non-executive director, responsible for reviewing financial reports and internal controls[111] Market Trends and Strategy - The antibody-drug conjugate industry is experiencing rapid growth, with a focus on expanding indications to non-tumor diseases, including autoimmune diseases and infections[37] - The Chinese pharmaceutical industry is expected to enter a new round of industrial upgrades, particularly in the sterile preparation sector, due to the implementation of new EU GMP regulations and China's accession to PIC/S[36] - The company aims to increase the share of its service business to achieve higher profit margins and reduce reliance on customer capital expenditure fluctuations[39] - The company is exploring global expansion opportunities, particularly in regions with higher profit margins, such as the Middle East and Southeast Asia[60]

Financial Performance - Total revenue for 2023 was RMB 1,763,734, a decrease of 18.2% compared to RMB 2,156,869 in 2022[9]. - Gross profit for 2023 was RMB 336,050, down 31.2% from RMB 488,796 in 2022, resulting in a gross margin of 19.1%[9]. - The company reported a loss attributable to owners of RMB (113,473) in 2023, compared to a profit of RMB 87,461 in 2022[9]. - Total assets decreased by 9.6% to RMB 2,158,972 in 2023 from RMB 2,388,763 in 2022[9]. - The debt-to-asset ratio increased to 39.2% in 2023 from 27.8% in 2022[9]. - The company recorded a net loss of approximately RMB 151.3 million for the year, compared to a profit of approximately RMB 67.7 million for the previous year[138]. - The gross profit decreased by approximately RMB 152.7 million or 31.2% to about RMB 336.1 million, reflecting the decline in revenue[114]. - The overall gross margin decreased from 22.7% to 19.1% due to lower profitability across various segments[115]. - The company expects gradual improvement in gross profit and margin over the next few years as market share grows and globalization expands[118]. Revenue Breakdown - Revenue from the Fluid and Bioprocess Systems segment was RMB 611,292, accounting for 34.7% of total revenue[11]. - Revenue from Cleanroom and Automation Control Systems was RMB 441,209, representing 25.0% of total revenue[11]. - Revenue from mainland China accounted for approximately 95.3% of total revenue, down from 96.1% in the previous year[112]. - Revenue from the Fluid and Bioprocess Systems segment decreased by 30.4% to approximately RMB 611.3 million, primarily due to a reduction in uncompleted contracts and order amounts[105]. - Revenue from the Cleanroom and Automation Control Systems segment decreased by 14.2% to approximately RMB 441.2 million, mainly due to a decline in order amounts[106]. - Revenue from the Powder Solid Systems segment increased by 2.4% to approximately RMB 251.8 million, attributed to a higher number of uncompleted contracts at the beginning of the year[107]. - Revenue from the Life Science Consumables segment decreased by 21.9% to approximately RMB 303.4 million, primarily due to a reduction in order amounts[110]. - Revenue from the Pharmaceutical Equipment Distribution and Agency segment increased by 84.0% to approximately RMB 65.9 million, driven by an increase in uncompleted contracts and improved project execution efficiency[111]. Strategic Initiatives - The company plans to expand its product offerings and enhance R&D capabilities in the biopharmaceutical sector[14]. - The company is focusing on strategic partnerships to enhance market presence and operational efficiency[14]. - Future guidance indicates a continued emphasis on innovation and market expansion despite recent financial challenges[14]. - The company plans to introduce a significant number of new products developed with proprietary intellectual property over the next two to three years[28]. - The company is enhancing its manufacturing capabilities and digital tools to support the development of proprietary equipment products, aiming to replace its previous role as a core equipment agent[56]. - The company is focusing on restructuring its business model to create a more synergistic and efficient operation, seeking new technological solutions for cost-effective comprehensive solutions[41]. - The company aims to enhance its competitiveness in the global market by continuously improving its products, services, and spare parts in freeze-drying, filling, and inspection technologies[78]. Market Trends and Opportunities - The biopharmaceutical industry is experiencing a shift towards differentiated and competitive pipelines, with a focus on long-term innovative technologies like AI-driven drug development[33]. - The demand for medical beauty products, including hyaluronic acid and botulinum toxin, is driving opportunities for fermentation and sterile powder equipment and technology[34]. - The company is optimistic about the long-term trends in the cell and gene therapy industry, despite a temporary slowdown in investment in China[101]. - The company is actively involved in the development of advanced therapy medicinal products (ATMP), with a strategic goal to provide competitive sterile protection solutions globally[100]. Operational Developments - In 2023, the company officially launched new manufacturing centers in Shanghai and Shijiazhuang[17]. - The company has established a strategic partnership with Endress+Hauser in Shanghai to enhance its operational capabilities[17]. - The company launched a new continuous manufacturing R&D platform for solid dosage forms in October 2023[17]. - The company has completed the development of a lipid nanoparticle preparation system, which is high-throughput, automated, and compliant with GMP regulations[72]. - The company has launched the ContiFlex10 flexible continuous production system, promoting the development of continuous manufacturing in China[70]. Human Resources and Training - Employee costs for the year were approximately RMB 459.8 million, a slight increase of about 0.5% compared to RMB 457.5 million for the year ended December 31, 2022[147]. - The company had a total of 1,610 full-time employees as of December 31, 2023, a decrease of 303 employees compared to the previous year[147]. - The production team introduced a "Lean Operations Room" to enhance the skills of on-site personnel, integrating training, motivation, simulation, and practical operations[59]. - The company has invested in employee training and development to maintain a skilled and dedicated workforce[182]. Research and Development - The company is investing in R&D, allocating 15% of its revenue towards developing new technologies and improving existing products[161]. - The company has developed 12 technical application teams focusing on areas such as pharmaceutical automation, cleanroom technology, and biopharmaceutical processes, enhancing its technical capabilities[94]. - The introduction of an AI predictive model in collaboration with Zhejiang University aims to optimize laboratory operations and reduce personnel requirements[67]. Customer and Supplier Relations - The group’s major customers accounted for approximately 13.2% of total revenue for the year, with stable relationships maintained for 1 to 17 years[188]. - The group has implemented a series of policies to maintain close relationships with major customers, including customer complaint management and satisfaction surveys[188]. - The group has established stable relationships with several key suppliers, typically retaining one to three suppliers for major raw materials[190]. Sustainability and Compliance - The management team emphasized the importance of sustainability initiatives, aiming to reduce operational costs by 10% through eco-friendly practices[165]. - The group is committed to sustainable development and has complied with multiple environmental laws and regulations during the year[191]. - The company has implemented energy-saving research for cleanroom air conditioning, aligning with national carbon neutrality policies[67]. Future Outlook - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach $625 million[167]. - Overall, the company remains optimistic about future growth, driven by strong market demand and a robust pipeline of new products[159].

Revenue Performance - The total revenue for the year ended December 31, 2023, was approximately RMB 1,763.7 million, a decrease of 18.2% from RMB 2,156.9 million in 2022[1]. - The Fluid and Bioprocess Systems segment reported revenue of approximately RMB 611.3 million, down 30.4% from RMB 878.6 million in 2022, primarily due to a decrease in uncompleted contracts and order volume[2]. - The Cleanroom and Automation Control and Monitoring Systems segment saw revenue decline by 14.2% to approximately RMB 441.2 million from RMB 514.1 million, mainly due to a drop in order volume in 2023[3]. - The Powder Solid Systems segment experienced a revenue increase of 2.4%, reaching approximately RMB 251.8 million, attributed to a higher number of uncompleted contracts at the beginning of the year[5]. - The GMP Compliance Services segment's revenue decreased by 4.5% to approximately RMB 90.1 million from RMB 94.3 million, due to a reduction in order volume and lower conversion rates of COVID-19 related projects[6]. - The Life Science Consumables segment reported a revenue decline of 21.9% to approximately RMB 303.4 million from RMB 388.3 million, primarily due to decreased order volume in 2023[7]. - The Pharmaceutical Equipment Distribution and Agency segment saw a significant revenue increase of 84.0%, reaching approximately RMB 65.9 million from RMB 35.8 million, driven by an increase in uncompleted contracts and improved project execution efficiency[8]. Profitability and Financial Performance - The gross profit for the year was approximately RMB 336.1 million, a decrease of 31.2% from RMB 488.8 million in 2022, reflecting the decline in revenue[12]. - The gross profit margin for the year was 19.1%, down from 22.7% in the previous year[38]. - The company reported a loss attributable to owners of RMB 32.6 million from continuing operations, compared to a profit of RMB 104.2 million in the previous year[40]. - The total comprehensive income attributable to the company's owners for the year ended December 31, 2023, was RMB (123,931) thousand, compared to RMB 114,965 thousand for the year ended December 31, 2022, reflecting a significant decline[71]. - The company reported a net loss from continuing operations of RMB (43,065) thousand for the year ended December 31, 2023, compared to a loss of RMB (80,866) thousand for the previous year[71]. - The company reported a basic loss per share of RMB (32,607) for the year ended December 31, 2023, compared to a profit of RMB 104,237 for the year ended December 31, 2022[151]. Assets and Liabilities - The total assets decreased to RMB 2,158.97 million from RMB 2,388.76 million in the previous year[38]. - Total liabilities decreased from RMB 1,505,182 thousand in 2022 to RMB 1,383,499 thousand in 2023, a reduction of approximately 8.1%[94]. - Current assets decreased to RMB 1,573,819 thousand as of December 31, 2023, from RMB 1,801,007 thousand as of December 31, 2022, indicating a reduction of approximately 12.6%[72]. - The total equity attributable to the company's owners was RMB 775,473 thousand as of December 31, 2023, down from RMB 883,581 thousand as of December 31, 2022, reflecting a decrease of about 12.2%[72]. - Non-current assets totaled RMB 585,153 thousand as of December 31, 2023, slightly down from RMB 587,756 thousand as of December 31, 2022[72]. Research and Development - Research and development expenses decreased by RMB 14.9 million or 21.1% to approximately RMB 55.3 million, primarily due to a reduction in workforce and material consumption[65]. - The company is actively involved in the research and commercialization of new therapies, which is a key growth driver for its business[33]. - The company has introduced more cell-related equipment and systems in the ATMP industry in 2023, leveraging its proprietary intellectual property[35]. Market and Industry Outlook - The company is optimistic about the mid to long-term trends in the cell and gene therapy industry despite a recent slowdown in investment in China[35]. - The market for GLP-1 drugs is expected to continue driving research and production investments for several years, indicating a strong future outlook for the pharmaceutical industry[169]. - The expansion of production capacity for oral anti-tumor formulations and related CDMO services is creating new business opportunities in engineering technology systems[170]. - The company anticipates significant growth potential for domestic pharmaceutical service providers due to competitive pricing, stable supply chains, and effective after-sales service[171]. Operational Highlights - The company has classified assets held for sale at RMB 8,590 thousand as of December 31, 2023, with no comparable figure for the previous year[72]. - The company has been actively investing in human resources, regional expansion, and enhancing product and application solution capabilities, expecting to achieve more satisfactory business results[179]. - The company participated in and organized 55 events in 2023, including 16 exhibitions and 26 industry conferences, to enhance brand visibility[194].

Financial Performance - The company recorded revenue of approximately RMB 964 million, a decrease of about 45.6% compared to the same period in 2022 due to slow recovery post-COVID-19 and reduced capital expenditure investment sentiment[6]. - Total revenue for the first half of 2023 was approximately RMB 964.3 million, a decrease of about 12.7% compared to the same period in 2022[47]. - Revenue for the six months ended June 30, 2023, was RMB 964,269,000, a decrease of 12.7% from RMB 1,103,980,000 in the same period of 2022[137]. - The company reported a loss before tax of RMB 70,286,000, compared to a profit of RMB 48,234,000 in the previous year[137]. - The company recorded a loss of approximately RMB 72.2 million during the period, including net losses from H+E Pharma and S-Tec of RMB 63.9 million[85]. - The company expects to incur a loss of approximately RMB 60 million in the second half of 2023 due to bankruptcy applications from H+E Pharma GmbH and S-Tec GmbH[151]. - The net loss attributable to the owners of the company for the period was RMB 72,186 thousand, a significant decline from a profit of RMB 36,664 thousand in the same period last year[158]. Segment Performance - Revenue from the Fluid and Bioprocess Systems segment was RMB 371.8 million, accounting for 38.6% of total revenue, down 25.3% from RMB 497.8 million in 2022[48]. - The Cleanroom and Automation Control Systems segment generated RMB 222.1 million, representing 23.0% of total revenue, a decrease of 7.8% from RMB 240.9 million in 2022[48]. - The Powder Solid Systems segment saw an increase in revenue to RMB 129.6 million, up 19.1% from RMB 108.8 million in 2022, contributing 13.4% to total revenue[48]. - GMP Compliance Services revenue increased by 13.9% to RMB 50.4 million, representing 5.2% of total revenue[48]. - Life Science Consumables revenue decreased by 17.6% to RMB 161.2 million, accounting for 16.7% of total revenue[48]. - The Pharmaceutical Equipment Distribution and Agency segment experienced significant growth, with revenue rising 74.7% to RMB 29.2 million, contributing 3.1% to total revenue[48]. Market Trends and Strategic Focus - The company observed a potential recovery in capital expenditure projects within the pharmaceutical industry in July 2023, indicating a more active market[6]. - The company is focusing on enhancing its service business to meet broader customer needs, which is expected to provide new significant revenue sources and higher profit margins in the future[7]. - The company is actively investing in human resources, regional expansion, and enhancing product and application solution capabilities to achieve stronger business outcomes[8]. - The company is restructuring its product lines to provide more cost-effective integrated solutions, which will enhance its adaptability to a more competitive environment[10]. - The company is positioned to leverage its high-level technical solutions and compliance verification knowledge to capitalize on opportunities arising from stricter drug regulation in China[2]. - The company is witnessing a shift in the pharmaceutical equipment market, with domestic suppliers becoming more competitive in terms of price, quality, and supply chain reliability[4]. Research and Development - The company has developed 12 technical application teams to enhance its technology solutions across various business units[41]. - The company is focusing on continuous manufacturing technologies and aims to collaborate with academic institutions and strategic partners for further development[41]. - The group has completed the development of a pre-filled syringe (PFS) and combination filling line compatible with ampoules and vials, enhancing its competitive advantage for future business development[31]. - The group has strengthened research on particle size control technology, developing laboratory grinding machines to provide application solutions for particle size control from micrometers to nanometers[29]. - The development of fermentation processes and suspension culture bioreactors has been completed, enhancing the group's capabilities in biopharmaceutical core process systems[38]. Operational Efficiency - The company is enhancing its digital tools and data analysis efficiency through the establishment of standardized data information systems at new production facilities[21]. - The group has established a business intelligence data visualization platform to provide clients with various templates for data processing and visualization[36]. - The company has implemented a digital integration management system for project execution, ensuring seamless connection from concept design to project completion[22]. Financial Position and Liabilities - As of June 30, 2023, the total current assets of the group amounted to approximately RMB 1,714.6 million, a decrease of about RMB 86.4 million from RMB 1,801.0 million as of December 31, 2022[88]. - The group's total liabilities to equity ratio increased from approximately 27.8% as of December 31, 2022, to about 34.8% as of June 30, 2023[89]. - The group had a total equity of approximately RMB 859.5 million as of June 30, 2023, down from RMB 896.9 million as of December 31, 2022[98]. - The company's total liabilities as of June 30, 2023, were RMB 1,492,008,000, a slight decrease from RMB 1,505,182,000 as of December 31, 2022[154]. Governance and Management - The company has adopted and is committed to implementing corporate governance codes to enhance management standards and protect shareholder interests[119]. - The roles of Chairman and CEO are held by the same individual, Mr. He Guoqiang, which the board believes enhances leadership and strategic planning efficiency[122]. - All directors confirmed compliance with the standards set forth in the code of conduct during the review period[123].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Austar Lifesciences Limited 奧星生命科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6118） 截至 年 月 日止六個月之 2023 6 30 中期業績公告 本集團財務摘要 截至6月30日止六個月 2023年 2022年 人民幣千元 人民幣千元 （未經審核） （未經審核） 收入 964,269 1,103,980 毛利 147,273 235,735 除所得稅前（損失）╱溢利 (70,286) 48,234 本公司擁有人應佔（損失）╱溢利 (39,944) 45,843 毛利率 15.3% 21.4% ...

Financial Performance - In 2022, the company's revenue was RMB 87,461,000, a decrease from RMB 277,300,000 in 2021, representing a decline of approximately 68.4%[66]. - The gross profit for 2022 was RMB 462,669,000, compared to RMB 479,008,000 in 2021, indicating a slight decrease of about 3.4%[66]. - The profit attributable to owners of the company for 2022 was RMB 0, down from RMB 0.54 in 2021, reflecting a significant decline[66]. - The basic and diluted earnings per share for 2022 were RMB 0.17, compared to RMB 0.54 in 2021, marking a decrease of approximately 68.5%[66]. - Revenue for the year ended December 31, 2022, was RMB 2,228,644, representing a 10.6% increase from RMB 2,015,028 in 2021[74]. - Net profit attributable to the owners of the company was RMB 87,461, a significant decline from RMB 277,300 in 2021[74]. - The total revenue for the year was approximately RMB 2,228.6 million, representing a growth of about 10.6% compared to the previous year[181]. Shareholder Information - As of December 31, 2022, the company's reserves available for distribution to shareholders amounted to RMB 434,700,000, an increase from RMB 415,313,000 as of December 31, 2021, representing a growth of approximately 3.34%[1]. - Mr. He Guoqiang holds 335,929,000 shares in the company, representing 65.54% of the total equity, while his spouse holds 3,750,000 shares, accounting for 0.73%[7]. - The company’s major shareholder, Kai Rui Holdings, is fully owned by Mr. He Guoqiang, indicating a concentrated ownership structure[8]. Corporate Governance - The company has established five professional committees, including the Audit Committee and the Remuneration Committee, to ensure effective governance and oversight[31]. - The board of directors has complied with the listing rules, maintaining at least three independent non-executive directors, constituting at least one-third of the board[21]. - The company recognizes the importance of good corporate governance in enhancing management standards and protecting shareholder interests[18]. - The company is committed to evaluating the independence of its non-executive directors annually to ensure unbiased decision-making[34]. - The company plans to continue monitoring its governance mechanisms annually to ensure compliance with listing rules[40]. Business Segments and Revenue Contribution - The revenue contribution by business segment in 2022 showed that Fluid and Bioprocess Systems accounted for 42.7%, Cleanroom and Automation Control and Monitoring Systems for 23.1%, and Life Science Consumables for 17.4%[68]. - The fluid and bioprocess systems segment generated RMB 950,341 in revenue, accounting for 42.7% of total revenue[75]. - The cleanroom and automation control segment contributed RMB 514,070, representing 23.1% of total revenue[75]. - The revenue from the Powder Solid Systems business segment increased significantly by approximately RMB 107.5 million or 77.7% to about RMB 245.8 million, driven by investments in new products[183]. - The GMP Compliance Services business segment's revenue rose by approximately RMB 28.2 million or 42.7% to RMB 94.3 million, stimulated by new international standards and regulations[184]. - The revenue from the Life Science Consumables business segment decreased by approximately RMB 32.8 million or 7.8% to about RMB 388.3 million, attributed to a decline in business related to COVID-19 vaccine production[185]. Market Expansion and Strategic Initiatives - The company signed its first pharmaceutical engineering contract in Algeria, marking a significant step in market expansion[79]. - The company is focusing on digital transformation projects for major domestic pharmaceutical enterprises, enhancing operational efficiency[82]. - The company is focusing on the development of new products and services in the cell and gene therapy sector, which is expected to drive future growth[173]. - The company plans to launch more cell-related equipment and systems in the ATMP industry starting in 2023, leveraging its proprietary intellectual property[176]. - The company has established a growth-driving team for its service business to increase revenue through more proactive approaches and action plans[179]. Research and Development - Research and development expenses increased by approximately RMB 4.6 million or 7.0% to about RMB 70.2 million, primarily due to increased spending on new product and technology development[195]. - The company has achieved three invention patents and seven utility model patents through collaboration with Tianjin University on energy-saving strategies[146]. - The company has developed 12 technology application teams focusing on areas such as pharmaceutical automation, cleanroom technology, and biopharmaceutical processes[149]. Operational Challenges and Future Outlook - The company anticipates that the adjustment of pandemic prevention policies in December 2022 will lead to an increase in new pharmaceutical projects and the resumption of capital expenditure investments[99]. - The order amount decreased by about 11.5% compared to the same period in 2021 due to difficulties in communication and meeting arrangements caused by the pandemic[102]. - The order amount for the Fluid and Bioprocess Systems segment was approximately RMB 777.4 million, a decrease of 35.6% from RMB 1,207.5 million in the previous year[106][107]. - The total order amount for the group was RMB 2,356.4 million, a decrease of 11.5% from RMB 2,662.9 million in the previous year[106]. Product Development and Innovation - The company launched the WAVE single-use bioreactor in July 2022, which is crucial for cell therapy and immune cell expansion processes[120]. - A new product brand, vivafill, was established following the acquisition of the BOSTA business to enhance brand recognition in sterile product filling and freeze-drying solutions[142]. - The company is developing a new closed isolator system, with the first unit completed and a second more complex unit expected to be finished in Q1 2023[148]. - The company has developed a data analysis system to assist clients in analyzing and predicting bioreaction processes, enhancing product lifecycle research[117].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Austar Lifesciences Limited 奧星生命科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6118） 截至 年 月 日止年度 2022 12 31 年度業績公告 2022年 2021年 人民幣千元 人民幣千元 收入 2,228,644 2,015,028 毛利 462,669 479,008 除所得稅前溢利 86,485 319,225 本公司擁有人應佔溢利 87,461 277,300 資產總額 2,388,763 2,044,777 資產淨額 883,581 788,420 ...